Search
Search Results
-
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial
PurposeResistance to HER2 (ErbB2)-targeted therapy may be mediated by other members of the ErbB family. We investigated the efficacy and safety of...
-
A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif® in healthy Chinese subjects
ObjectiveAfatinib is an oral, irreversible ErbB family blocker. It binds covalently to the kinase domains of epidermal growth factor (EGFR), HER2 and...
-
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
BackgroundHER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as...
-
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
BackgroundGlioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Amplification or overexpression of the epidermal...
-
Afatinib is active in osteosarcoma in osteosarcoma cell lines
PurposeOsteosarcoma is the most common bone tumor, mainly affecting adolescents and young adults, and metastatic disease has poor outcomes with a...
-
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors
Background Afatinib, an irreversible ErbB family blocker, has shown synergistic antitumor activity and manageable tolerability in combination with...
-
Regeneration of the heart: from molecular mechanisms to clinical therapeutics
Heart injury such as myocardial infarction leads to cardiomyocyte loss, fibrotic tissue deposition, and scar formation. These changes reduce cardiac...
-
Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment
BackgroundThe efficacy of afatinib or pyrotinib has been demonstrated in HER2-positive advanced non-small cell lung cancer (NSCLC) patients; however,...
-
A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management
BackgroundMultiple case reports and case series have been published on heart failure due to epidermal growth factor receptor tyrosine kinase...
-
MUC16: clinical targets with great potential
Mucin 16 (MUC16) is a membrane-bound mucin that is abnormally expressed or mutated in a variety of diseases, especially tumors, while being expressed...
-
Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors
Purpose of ReviewTo provide a detailed overview of cardiovascular adverse events associated with the use of tyrosine kinase inhibitors across...
-
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is the sixth most frequent cancer, with tobacco, alcohol and...
-
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
In the absence of suitable molecular markers, non-small cell lung cancer (NSCLC) patients have to be treated with chemotherapy with poor results at...
-
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell...
-
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC)...
-
Doxorubicin Cardiotoxicity: Pathophysiology Updates
Purpose of reviewDoxorubicin has long been known to cause cardiotoxicity, yet our understanding of its pathophysiologic mechanisms remains...
-
Epigenomic and transcriptomic landsca** unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors
PurposeNon-functioning pituitary neuroendocrine tumors are challengingly diagnosed tumors in the clinic. Transsphenoidal surgery remains the...
-
Sex Differences in Cardiomyopathy
Purpose of ReviewHeart failure (HF) is a significant cause of morbidity and mortality worldwide with unique phenotypes in men and women....
-
Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
BackgroundGiven that aberrant activation of epidermal growth factor receptor family receptors (ErbB) is a common event in oral squamous cell...
-
